Invitation to Make a Positive Impact

Invitation to Make a Positive ImpactEstablished in 1996, the Prostate Cancer Research Institute was founded to provide current, unbiased information to men who face the intimi-dating prospect of choosing their own treatment.

PCRI believes that patients empowered with understandable education-al and medical information will ultimately benefit with better cure rates and an improved quality of life.

We invite you to participate in this year’s Prostate Cancer Conference in Los Angeles, California on September 7-9, 2012.

This is the thirteenth year PCRI is hosting this prestigious event. An impressive lineup of world-renowned prostate cancer experts will be presenting current information and cutting-edge research related to treatment and lifestyle issues.

This three-day event is expected to attract more than 800 prostate can-cer survivors, physicians, patient advocates, researchers and health-care professionals from around the world. The conference proceedings will be videotaped and distributed glob-ally to approximately 700 support groups, reaching thousands of prostate cancer survivors. The PCRI conference is a unique opportunity to reach a diverse group of stakeholders in the prostate cancer community.

Please review the accompanying Sponsoring & Exhibiting Opportunities and determine your level of invovle-ment and participation. If you need additional information or have any questions, please call 310.743.2116 or e-mail [email protected].

We look forward to seeing you in Los Angeles this September!

Sincerely,

Mark Scholz, MDExecutive Director

Prostate Cancer Research Institute 2012 CONFERENCE INVITATION - 2

Mark Scholz, MDPCRI Executive Director

About PCRI

MissionThe Prostate Cancer Research Institute is a 501 (c)(3) charitable not-for-profit organization whose mission is to improve the quality of men’s lives by supporting research and disseminat-ing information that educates and empowers patients, families and the medical community.

PCRI’s main objective is to educate patients, their families and physicians about prostate cancer by providing the most current information on prostate cancer diagnosis, staging, treatments and available resources.

PCRI believes that a patient who understands his disease and treatment options will be em-powered to communicate more effectively with his physician(s), and will obtain a better out-come. PCRI uses all available communication tools and programs, including a helpline, a quarterly and a weekly newsletter, website and professional conferences to accomplish this important educational objective.

BackgroundPCRI was founded in 1996 by Mark C. Scholz, MD and Stephen B. Strum, MD; two interna-tionally recognized medical oncologists specializing in prostate cancer, with support from the Daniel Freeman Hospital Foundation in Southern California.

Dr. Scholz and Dr. Strum’s vision was that an organization providing insightful clinical re-search, in conjunction with educational activities directed at both the patient and physician, would greatly enhance outcomes for prostate cancer patients everywhere.

Working after hours to contribute their professional skills to cutting-edge work on prostate cancer, Scholz and Strum made the results of their own clinical research and the work of other researchers available to patients and physicians. As a result, PCRI has been involved in impor-tant developments in prostate cancer therapy, discoveries that have a direct effect on the quality of life for men with prostate cancer.

2012 CONFERENCE INVITATION - 3Prostate Cancer Research Institute

PCRI Support LinePrograms

Prostate cancer comes in many forms and complex variations. Newly diagnosed men and their families are al-most always in a state of shock following their diagnosis, which can often impair the ability to think clearly and formulate a course of action.

Our support line staff facilitators receive up to fifty inquiries a day about prostate cancer. Calls and e-mails come in from all over the world, and come from patients, family members, friends, and even physicians. Our knowledgeable staff facilitators, based out of Los Angeles, California and Sanibel, Florida, work to provide cus-tomized medical information relevant to each individual’s needs.

Our goal is to connect the caller with state-of-the-art resources that raise the effectiveness of dialogue between the patient and his physician, while refraining from giving actual medical advice. The valuable service the sup-port line provides is magnified because technology is advancing rapidly, and what constitutes the best treatment is constantly evolving. Only well-trained, fully-involved staff facilitators can stay abreast of all these new devel-opments. The PCRI is happy to provide this service free of charge via both phone and e-mail.

NewslettersPCRI Insights

PCRI publishes a quarterly newsletter called Insights, which has a circulation of over 20,000 all over the world.

Its goal is to educate, inform and empower the prostate cancer community with the latest advances in prostate cancer treatment and prevention. Our target audience covers the wide range of sophisticated patients, research-ers, primary care physicians, urologists, radiation therapists and medical oncologists.

PCRI provides cutting-edge information about the most advanced thinking on prostate cancer management and men’s health. Anyone is welcome to receive a free subscription to Insights via regular mail, e-mail or both; and all back issues are available for download in PDF format on the PCRI website.

In December 2011, PCRI launched a brand-new weekly e-newsletter, PCRI Weekly, to complement the quarterly Insights newsletter and provide our readers with more frequent updates. PCRI Weekly is posted to the PCRI website every Thursday, and contains up-to-date, detailed information about the latest developments in prostate cancer treatment.

Every week, PCRI selects an abstract from an important study relevant to prostate cancer research and sum-marizes the results, with an easy-to-understand “takeaway message” for men with prostate cancer. Although the focus of this newsletter is on medical news, PCRI will publish occasional feature and human interest stories as well. Back issues of PCRI Weekly are available on the PCRI website.

NEW! PCRI Weekly


ProgramsAdvocacyWhile advocacy is not PCRI’s primary goal, the organization has attained a respected and credible voice in the medical, political and public arena. PCRI has judiciously come out in support of worthy prostate cancer-related causes to encourage increased research and to expedite FDA approval of new therapies.

In its efforts to speak and advocate on behalf of patients everywhere, PCRI and its staff have been cited in several news stories published by the following media organizations: •ABCWorldNewsTonight •NBC-TV •TheLosAngelesTimes •TheNewYorkTimes •TheWallStreetJournal •TheWashingtonPost •TVNZ:TheNewsofNewZealand

ResearchThe allocation of research dollars is managed by a distinguished board of physicians representing all the major disciplines involved in prostate cancer care. All serve as volunteers without any financial compensation from the PCRI.

Board Member Specialty AffiliationDuke Bahn, MD Radiology Prostate Institute of AmericaStanley Brosman, MD Urology Professor of Urology, UCLAArthur Lurvey, MD Endocrinology Chief Medical Officer, MedicareMark Scholz, MD Medical Oncology Executive Director, PCRIMichael Steinberg, MD Radiation Therapy Department Chief, UCLA

In addition to their extensive research experience, all of these doctors participate in the day-to-day care of men with prostate cancer, which provides a practical clinical perspective for evaluating the value of research propos-als.

In 2011, PCRI supported new, potentially breakthrough work at the following institutions: •MayoClinic:Researchintonewmethodstoinduceapatient’simmunesystemtoattackcancer. •UniversityofNijmegen,theNetherlands:ResearchtoimproveMRIimagingtodetectearly cancer spread. •UniversityofToronto:ResearchintoActiveSurveillanceformenwithearlystagedisease. •JohnWayneCancerInstitute:Researchprogramstoidentifyeffective,lessinvasivewaysto screen, diagnose and treat brain tumors, melanoma, and breast cancer. •ProstateCancerFoundation:Researchintobettertreatmentsforprostatecancer.


ProgramsPCRI ConferencesEvery September (prostate cancer awareness month), PCRI conferences bring hundreds of patients, caregivers, physicians and institutional supporters together for a weekend of interactive sessions and lectures. The 2011 PCRI conference drew more than 700 attendees from 41 states and nine countries.

Delivered by leading physicians, academics and scientists, the presentations are recorded on video and distribut-ed to hundreds of support group meetings around the world. Made possible by generous individual and corpo-rate supporters and a legion of dedicated volunteers, this annual conference brings people together who have an interest in topics related to prostate cancer.

In addition to hearing from experts with a wealth of knowledge about prostate cancer, the conference also allows attendees the benefit of connecting with fellow patients and others in the prostate cancer community. Attendees have the opportunity to attend the following sessions throughout the weekend:•Roundtablediscussion:Apanelofconferencefacultydiscusstheirmedicalopinionsonrealclinical cases. •Q&AwiththeSpeakers:Conferenceattendeesmayaskfacultyspecificquestionsinamoreintimate setting. •AsktheExperts:90-minuteinteractivesessionsthatfocusontopicssuchasMedicalOncology,Urol- ogy, Radiation Oncology, Immunotherapy, nutrition and a prostate-friendly lifestyle. •SupportGroups:WiththehelpofPCRI’spartnersandprofessionalfacilitators,supportgroupmeet- ings are offered to patients and their significant others.


NEW! PCRI Mentoring Program (coming this spring)In our continued effort to provide men with unbiased, scientifically accurate information about prostate cancer treatment options, PCRI is in the process of creating an educational program - a comprehensive training and mentoring course - to equip support group leaders across the country with the knowledge needed in a variety of topics to be effective and supportive leaders.

The online course will consist of a series of webinars by well-known medical professionals who are highly re-garded in their respective fields of prostate cancer research. The course will cover a wide range of topics, includ-ing (but not limited to) active surveillance, screening and prevention, imaging, and a detailed overview of the five “shades” of prostate cancer. It will be set up in the format of a regular online class, with required reading, lectures, homework and 2-3 exams.

The curriculum for the PCRI mentoring program is currently in the works, and we plan to launch in the spring of 2012.

NEW! PCRI Blue CommunityIn September 2011, PCRI launched a new website called the Blue Community, for men with prostate cancer and their families to network and share their experiences with others in their same risk category, or “shade” of blue (the awareness color for prostate cancer).

The PCRI Blue Community introduces the concept of different shades of blue as a way to navigate the various types of prostate cancer, and provides online discussion forums as a way for men to connect with one another. The Blue Community is rapidly growing, with over 400 active users taking advantage of the site.

WebsiteIn 1998, PCRI adopted the internet as an educational tool. Our website, PCRI.org, contains more than 5,000 pages of information, and currently averages more than 75,000 visitors and 900,000 page views per month.

PCRI.org contains a wealth of content, including medical articles by leading prostate cancer specialists, risk evaluation tools, information about clinical trials, support groups, past issues of our newsletters, patient assis-tance programs, videos and more.

The website provides an introduction to assist a newly diagnosed patient in understanding the biology and extent of his prostate cancer. This understanding is the first step to empowerment that leads to determining his choice of if, when and how to treat his disease.

Programs

ManagementPCRI undergoes an annual financial audit, and consistently receives a “Best in America” seal of approval from the Independent Charities of America.

The Independent Charities Seal of Excellence is awarded after rigorous indepen-dent review. Only charities meeting the highest standards of public accountability, program effectiveness, and cost effectiveness are eligible. These standards include those required by the U.S. government for inclusion in the Combined Federal Campaign, possibly the most exclusive fund drive in the world.

Of the 1 million charities operating in the United States today, it is estimated that fewer than 50,000 – or 5 percent – meet or exceed these standards, and, of those, fewer than 2,000 have been awarded the Seal.


Chester A. Swenson, PresidentJeromeSeliger,PhD,Vice PresidentBarryL.Friedman,JD,SecretaryT.KentGraham,TreasurerDukeK.Bahn,MDStanley A. Brosman, MD

Mark Scholz, MD, Executive DirectorCathy Williams, Chief Operating OfficerTomGallatin,General Manager/GrantsLaurie Sorrow, Programs Coordinator

PCRI Staff

Scott CohenArthur N. Lurvey, MDJerryPetersClaudia B. Sangster, Esq.Mark C. Scholz, MD, PCRI Co-founderMichael Steinberg, MD, FAC

Madhu Rajaraman, Senior Writer/EditorJanManarite,Senior Educational FacilitatorNathan Roundy, Educational FacilitatorSilvia Cooper, Educational Facilitator

Contact Information

Prostate Cancer Research Institute5777 W. Century Blvd., Suite 800Los Angeles, CA 90045

(800) 641-PCRI (7274)Administrative (310) 743-2116Fax (310) 743-2113Helpline (310) 743-2110

E-mail: [email protected]: www.pcri.orgBlue Community: www.pcribc.org


Board of DirectorsPCRI Board & Staff

Sponsoring & Exhibiting OpportunitiesUNDERWRITING SPONSORMINIMUM CONTRIBUTION OF $50,000• Organization name and logo printed on: Banner at conference site Conference brochure Back cover of official program book Conference tote bags ConferenceDVDs Step and Repeat PCRI website, with link posted through September 30, 2012• Event hosting (promotional reception, breakfast, lunch, etc.)• Complimentary hospitality room• Acknowledgement on conference advertising• Organization information inserted in conference tote bags• 6’ x 40’ display/exhibit area• Organizational write-up in PCRI Insights newsletter (February, May, August or November issue)• Namedlecture-TBD• Registration and badges for up to 20 people• 20 tickets to Saturday night event• 20 tickets to Friday night reception• Acknowledgement during Saturday night event and Friday night reception

PLATINUM SPONSORMINIMUM CONTRIBUTION OF $30,000• Organization name and logo printed on: Conference brochure Inside back/front cover of official program book ConferenceDVDs Step and Repeat PCRI website, with link posted through September 30, 2012• Event hosting (promotional reception, breakfast, lunch, etc.)• Acknowledgement on conference advertising• Organization information inserted in conference tote bags• 6’ x 20’ display/exhibit area• Organizational write-up in PCRI Insights newsletter (February, May, August or November issue)• Namedlecture-TBD• Registration and badges for up to 15 people• 15 tickets to Saturday night event• 15 tickets to Friday night reception• Acknowledgement during Saturday night event and Friday night reception

Prostate Cancer Research Institute Sponsoring & Exhibiting Opportunities - 1

Sponsoring & Exhibiting OpportunitiesGOLD SPONSORMINIMUM CONTRIBUTION OF $20,000• Organization name and logo printed on: Conference brochure Goldpageofofficialprogrambook ConferenceDVDs PCRI website, with link posted through September 30, 2012• Acknowledgement on conference advertising• Organization information inserted in conference tote bags• 6’ x 15’ display/exhibit area• Organizational write-up in PCRI Insights newsletter (February, May, August or November issue)• Registration and badges for up to 10 people• 10 tickets to Saturday night event• 10 tickets to Friday night reception

SILVER SPONSORMINIMUM CONTRIBUTION OF $10,000• Organization name and logo printed on: Conference brochure Silver page of official program book ConferenceDVDs PCRI website, with link posted through September 30, 2012• Acknowledgement on conference advertising• Organization information inserted in conference tote bags• 6’ x 10’ display/exhibit area• Registration and badges for up to 5 people• 5 tickets to Friday night reception

EXHIBITORMINIMUM CONTRIBUTION OF $5,000• Organization name and logo printed on: Conference brochure Black & white page of official program book• Acknowledgement on conference advertising• Organization information inserted in conference tote bags• 6’ x 8’ display/exhibit area• Registration and badges for up to 3 people

Prostate Cancer Research Institute Sponsoring & Exhibiting Opportunities - 2

Sponsoring & Exhibiting Opportunities1. Please indicate your level of involvement

Underwriting Sponsor ($50,000)Platinum Sponsor ($30,000)GoldSponsor($20,000)Silver Sponsor ($10,000)Exhibitor ($5,000)Other ($__________)

2. Dash for Dads — South Bay:If you would like to support the June 17 “Dash for Dads” race in Manhattan Beach, please indicate your level of involvement.

$5,000$1,000 $500Other($__________)

Prostate Cancer Research Institute APPLICATION - 1

3. Contact InformationPlease provide information for the contact person from your organization who will receive all correspondence for this event. Please provide an e-mail address if you wish to receive additional information and updates about the event.

Organization Name

Primary ContactStreet Address

City, State, Zip

PhoneE-mail

4. Official Program Book

Check here if you wish to use the information in #3 above for official program book.

Check here if you are attaching a separate document or instruction on design/name to use.

$2,500

Sponsoring & Exhibiting Opportunities


5. Description of Products and ServicesAll applications must be accompanied by a complete description of product/service information and literature to be dis-played. If you need more space, please attach a separate sheet with the required information.

6. Exhibiting/DisplayingPCRI encourages exchanges and interaction among members of the prostate cancer community. The exhibit hall is designed to make this exchange possible.

Check here if you are interested in setting up an exhibit and wish to reserve an exhibit space.

In the space below, please list any special requirements you may have:

Exhibit space availability and assignments are based on the fol-lowing:

a. Level of participation (see #1 above)b. Amount of space requiredc. Date application is received

Sponsoring & Exhibiting Opportunities7. Payment TermsPlease see Application page 4 for full Conference Terms & Conditions.

The Prostate Cancer Research Institute (PCRI) is a 501 (c)(3) not-for-profit charitable organization. Its Fed-eral Tax ID # is 95-4617875.

Payments relating to the 2012 Conference are consid-ered direct support to PCRI’s programs, and are tax-deductible (please consult your tax professional).

Upon receipt of your payment and upon request, PCRI will issue a donation acknowledgment letter.

Please make your check payable to “Prostate Cancer Research Institute.” Exhibitors not making timely pay-ments may forfeit their reserved space.

8. AgreementWe, the exhibiting organization, have received, read and accepted the conditions for exhibiting, as outlined in the Conference Terms and Conditions (Application page 4). We and our representatives agree to abide by the exhibitor rules and regulations, all of the terms of which are made a part hereof by this reference and fully incorporated herein.

Signature_______________________________________Date___________________________________________Printed Name____________________________________Title____________________________________________

PLEASE DO NOT WRITE BELOW THE LINE.

Please return completed application to:

Prostate Cancer Research Institute (PCRI)Sponsorships & Exhibits

5777 W. Century Blvd., Suite 800Los Angeles, CA 90045

Organization Name

Primary Contact

Street Address

City, State, Zip

Phone

E-mail


Terms & Conditions2011 Prostate Cancer ConferenceTerms and Conditions

I. Scope. These terms and conditions shall be binding upon Prostate Cancer Research Institute (PCRI), Ex-hibitor and their respective Agents and representatives, including but not limited to Exhibitor, contracted labor such as Customer Appointed Contractors and Installation and Dismantle Companies, and any other party with aninterestintheGoods.Eachshallhavethebenefitofandbeboundbyallprovisionsstatedherein,includingbut not limited to time limits and limitations of liability.

II. Exhibitor to PCRI. Mutual Obligation Indemnification. Exhibitor shall defend, hold harmless and indemnify PCRI from and against any claims, lawsuits, demands, liability, costs and expenses, including rea-sonable attorney’s fees and court costs, resulting from any injury to or death of persons, or damage to property otherthanGoods,relatingtoorarisingfromperformanceofservicesherein.Customeragreestoindemnifyandhold PCRI harmless for any and all acts of its representatives and agents, including but not limited to Exhibitor Appointed Contractors and Installation and Dismantle Companies, any subtenant or other user of its space or any agents or employees engaged in business on behalf of Exhibitor or present at Exhibitor’s invitation, including supervision of labor. Exhibitor’s obligations under this provision shall not apply to PCRI’s own negligence and/or willfulmisconduct.EXHIBITORACKNOWLEDGESTHATTHESHOWSITEISANACTIVEWORKZONEANDCUSTOMER,ITSAGENTS,EMPLOYEESANDREPRESENATIVESAREPRESENTATTHEIROWNRISK.

III. PCRI to Exhibitor. TotheextentofPCRI’sownnegligenceand/orwillfulmisconduct,andsubjecttothelimitations of liability below, PCRI shall defend, hold harmless and indemnify Exhibitor from and against any claims, lawsuits, demands, liability, costs and expenses including reasonable attorney’s fees and court costs result-ingfromanyinjurytoordeathofpersonordamagetopropertyotherthanGoods.PCRI’sobligationsunderthisprovision shall not apply to claims for bodily injury arising a) from Exhibitor’s presence in areas which have been marked as “off limits to Exhibitors”, and b) when Exhibitors are present in the facility prior or subsequent to the effective dates or hours of Exhibitor’s space lease with show management.

IV. Disclaimer and Limitation of Liability. UNDERNOCIRCUMSTANCESWILLANYPARTYBELIA-BLEFORSPECIAL,INCIDIENTAL,CONSEQUENTIAL,INDIRECTORPUNITIVEDAMANGES,INCLUD-INGBUTNOTLIMITEDTOLOSSOFPROFITSORINCOME.PCRISHALLBELIABLE,SUBJECTTOTHELIMITIATIONCONTAINEDHEREIN,FORLOSSORDAMAGETOGOODSONLYIFSUCHLOSSORDAMAGEISCAUSEDBYTHEDIRECTNEGLGIENCEORWILLFULMISCONDUCTOFPCRI.CLAIMSPRESENTEDFORLOSSORDAMAGEARISINGOUTOFANYOTHERINCIDENTSWILLBEDENIED.

V. Insurance. PCRI does not offer of provide insurance. It is the obligation of Exhibitor to ensure goods are insured at all times. Loss or theft of the goods in storage or in transit to and from the show and or while on the show floor is the sole responsibility of Exhibitor. Exhibitor should arrange for all Risk Coverage.

VI. Liability Insurance. Exhibitor shall provide PCRI with a certificate of liability insurance naming “2011Prostate Cancer Conference” as an additional named insured.

Prostate Cancer Research Institute APPLICATION - 4 Agen

da &

Lear

ning O

bjecti

ves

Agen

da &

Lear

ning O

bjecti

ves

FAC

ULT

YTO

PIC

Nat

han

Rou

ndy,

PC

RI E

duca

tiona

l Fac

ilita

tor

Pros

tate

Can

cer 1

01Ja

n M

anar

ite, P

CRI

Sen

ior E

duca

tiona

l Fac

ilita

tor

Pros

tate

Can

cer 2

01

FAC

ULT

YTO

PIC

LEA

RN

ING

OBJ

ECTI

VES

Dav

id H

eber

, MD

D

irect

or, U

CLA

Cen

ter f

or H

uman

Nut

ritio

nLi

fest

yle

Cha

nges

, Sup

plem

ents

, Pre

scrip

tions

and

ev

en S

urge

ry to

Pro

mot

e th

e “P

erfe

ct” B

ody.

•D

iets

that

affe

ct c

ance

r gro

wth

•Ex

erci

se th

at b

uild

s lea

n bo

dy m

ass

•Su

pple

men

ts th

at m

ay b

e de

lete

rious

for

canc

er p

atie

nts

•H

ow c

an su

rger

y m

ake

a di

ffere

nce?

•Pr

escr

iptio

n m

edic

atio

ns th

at p

rom

ote

a m

ore

lean

bod

yJo

hn B

lask

o, M

DRa

diat

ion

Onc

olog

ist, S

eattl

e Pr

osta

te In

stitu

teW

hatt

heH

eckDoYo

uDowith

aT

inyCan

cer?

Ther

agen

ics,

seed

impl

ants

•D

efine

par

amet

ers o

f app

ropr

iate

can

dida

tes

for a

ctiv

e su

rvei

llanc

e•

Imag

ing

and

biop

sy m

etho

ds fo

r sta

ging

and

m

onito

ring

pros

tate

can

cer

Ric

hard

Lam

, MD

Rese

arch

Dire

ctor

, Pro

stat

e O

ncol

ogy

Spec

ialis

tsTr

eatin

gHigh-

Risk

Pro

stateCan

cer

Prov

enge

,Zyt

iga,M

DV-

3100

,Den

osum

ab,A

lpha

radi

n•

Prot

ocol

s for

com

bini

ng ra

diat

ion,

bra

chy-

ther

apy

and

andr

ogen

dep

rivat

ion

•Re

view

the

late

st ta

rget

ing

tech

nolo

gy fo

r IM

RT,inc

ludi

ngC

alyp

so•

Pres

ent s

tatu

s of a

djuv

ant c

hem

othe

rapy

•Se

lectin

gm

enfo

rIM

RTto

pelvicl

ymph

no

des

Cha

rles

“Snu

ffy”

Mye

rs, M

DM

edic

al O

ncol

ogist

, Am

eric

an In

stitu

te fo

r Dise

ases

of t

he P

rost

ate

How

to M

anag

e Pr

osta

te C

ance

r if i

t Com

es B

ack

after

Su

rger

y or

Rad

iatio

n•

Role

of d

utes

terid

e w

ith in

term

itten

t hor

-m

one

bloc

kade

•Si

gnifi

canc

e of

PSA

dou

blin

g tim

e•

Des

igni

ng ta

rget

ed th

erap

y fo

r olig

omet

as-

tase

s•

Prot

ectiv

e eff

ect o

f Xge

va o

n ca

lciu

m lo

ss

and

canc

er p

rogr

essio

n

FRID

AY, S

EPTE

MB

ER 7

SATU

RD

AY, S

EPTE

MB

ER 8

Agen

da &

Lear

ning O

bjecti

ves

Rob

ert D

reic

er, M

D

Cha

irman

,Dep

artm

ento

fSolid

Tum

orO

ncolog

y,Cleve

land

Clin

ic

Trea

tingPr

ostateC

ance

rtha

thas

Metas

tasiz

ed•

Use

ofn

ewage

ntss

uch

asP

rove

nge,

Jevt

ana,

Cab

azita

xel,

Abi

rate

rone

•C

hem

o co

mbi

natio

ns a

nd sc

hedu

les

•Su

ppor

tive

ther

apy

with

Ava

stin

, Neu

last

a an

d A

rane

sp•

Bone

supp

ortw

ithX

geva

,Zom

eta&

Prov

enge

Euge

ne K

won

, MD

Prof

esso

r of U

rolo

gy, Th

e M

ayo

Clin

icTh

eCom

ingW

aveof

New

Tre

atm

ent

TAK-7

00,C

urster

sin,A

lpha

radi

n•

Futu

rero

leofM

DV-

3100

,Ipi

limum

ab,D

a-sa

tinib

and

XL-

184

•New

imag

ingbr

eakt

hrou

ghs,

such

asP

ET

scan

ning

, how

it w

ill a

ffect

sele

ctio

n of

th

erap

yJo

hn M

ulha

ll, M

DD

irect

or, M

ale

Sexu

al a

nd R

epro

duct

ive

Med

icin

e Pr

ogra

m,

Mem

orialS

loan

-Ketterin

gCan

cerC

enter

Prev

entin

gTr

eatm

ent-Re

latedSide

Effe

cts

•Kno

wco

mm

ondefi

nitio

nsand

cau

seso

fse

xual

dys

func

tion

•Le

arn

met

hods

to p

reve

nt o

r min

imiz

e th

e im

pact

of t

reat

men

t on

sexu

al d

ysfu

nctio

n•

Revi

ew m

oder

n m

edic

al &

surg

ical

trea

t-m

ents

for s

exua

l dys

func

tion

•D

iscus

s met

hods

to im

prov

e pa

tient

/doc

tor

com

mun

icat

ion

on se

xual

topi

csLo

ri B

uckl

ey, P

syD

Th

erap

ist, D

r. Lo

ri Bu

ckle

y &

Ass

ocia

tes

Issu

es o

f Int

imac

y•

Disc

uss m

etho

ds fo

r ove

rcom

ing

barr

iers

to

intim

acy,

such

as l

ow li

bido

and

ED

SATU

RD

AY, S

EPTE

MB

ER 8

(CO

NTI

NU

ED)

SUN

DAY

, SEP

TEM

BER

9

Mar

k M

oyad

, MD

Seni

or R

esea

rch

Ass

ocia

te, U

nive

rsity

of M

ichi

gan

Med

ical

Sch

ool

Mar

k Sc

holz

, MD

Med

ical

Dire

ctor

, Pro

stat

e O

ncol

ogy

Spec

ialis

ts

Satu

rday

review

,Q&A

8 A

M t

o 9

AM

•Que

stio

nson

prev

entio

n,tr

eatm

ent,

side

effec

ts a

nd su

pple

men

ts

Mar

k M

oyad

, MD

Seni

or R

esea

rch

Ass

ocia

te, U

nive

rsity

of M

ichi

gan

Med

ical

Sch

ool

Mar

k Sc

holz

, MD

Med

ical

Dire

ctor

, Pro

stat

e O

ncol

ogy

Spec

ialis

ts

Satu

rday

review

,Q&A

8 A

M t

o 9

AM

•Que

stio

nson

prev

entio

n,tr

eatm

ent,

side

effec

ts a

nd su

pple

men

ts

Agen

da &

Lear

ning O

bjecti

ves

ASK

TH

E EX

PERT

SM

icha

el S

tein

berg

, MD

Cha

ir of

Rad

iatio

n O

ncol

ogy,

UC

LA

Radi

atio

n•

Disc

uss v

ario

us ty

pes o

f rad

iatio

n in

clud

ing

IMRT

,Pro

ton

andBr

achy

ther

apy

•Re

view

pot

entia

l acu

te a

nd ch

roni

c sid

e ef

-fe

cts o

f rad

iatio

nSt

ephe

n St

rum

, MD

Med

ical

Onc

olog

istH

orm

one

Bloc

kade

Ric

hard

Lam

, MD

Che

mot

hera

py,L

upro

n,M

DV-

3100

,Zyt

iga,Firm

agon

•Le

arn

abou

t Xge

va th

erap

y fo

r tre

atm

ent o

f m

etas

tatic

dise

ase

•C

over

com

mon

type

s of c

hem

othe

rapy

, in

clud

ingTa

xotere

,Cab

azita

xel

Duk

e Ba

hn, M

DM

edic

al D

irect

or, P

rost

ate

Inst

itute

of A

mer

ica

Act

ive

Surv

eilla

nce

&Fo

cal Th

erap

y•

Disc

uss i

mag

ing

met

hods

for m

onito

ring

pros

tate

can

cer

•Re

view

adv

anta

ges a

nd d

isadv

anta

ges o

f fo

cal t

hera

py co

mpa

red

to tr

aditi

onal

trea

t-m

ent

•Kno

wth

edi

fficu

lties

assoc

iatedwith

acc

u-ra

te tu

mor

loca

lizat

ion

Dav

id H

eber

, MD

Nut

ritio

n an

d Fi

tnes

s•

Revi

ew th

e ro

le o

f die

t in

canc

er m

anag

e-m

ent

•U

nder

stan

d th

e im

pact

of d

iet o

n ca

ncer

gr

owth

•Id

entif

y w

hich

food

type

s are

del

eter

ious

an

d w

hich

can

inhi

bit c

ance

r gro

wth

Cha

rles

“Snu

ffy”

Mye

rs, M

DHor

mon

eTh

erap

y,Zy

tiga

•D

iscus

s and

roge

n bl

ocka

de in

its m

any

form

s, in

clud

ing

LHRH

ago

nist

s•

Und

erstan

dth

eev

olving

rolefo

rZyt

iga,

MDV-

3100

and

oth

erse

cond

aryho

rmon

al

inte

rven

tions

•Re

view

met

hods

for m

inim

izin

g th

e sid

e eff

ects

of a

ndro

gen

bloc

kade

Euge

ne K

won

, MD

Surg

ery

•Be

fam

iliar

with

all

the

new

est a

nd m

ost

com

mon

surg

ery

optio

ns•

Disc

uss p

oten

tial s

ide

effec

ts o

f tre

atm

ent,

incl

udin

g se

xual

dys

func

tion

SUN

DAY

, SEP

TEM

BER

9 (C

ON

TIN

UED

)

Invitation to Make a Positive Impact

Documents

Transcript of Invitation to Make a Positive Impact